Table 1 Strategies to design ferroptosis-inducing nanomaterial for cancer therapy
Strategy | Nanomaterial example | Ferroptosis components | References |
|---|---|---|---|
Producing reactive oxygen by Fenton reaction | Fe3O4/Gd2O3@CDDP@LF/RGD2 | Fe3O4, CDDP | [49] |
Gox@MOF(Fe)@CCM | Fe2+, Fe3+, GOx | [50] | |
AuFCSP MOFs | Fe2+, Fe3+, Au NPs | [51] | |
Inhibiting the activity of GXP4 | RSL3@COF-Fc | Fc, RSL3 | [56] |
HMPB/ ML210@TA-BLM-Fe3+ | Fe2+, Fe3+, ML210 | [57] | |
Consuming intracellular GSH | CA-OH-Fe3+/Gd3+@P-SS-D | Fe2+, Fe3+, CA | [58] |
siMCT4-PAMAM-PEG-TK-Fc@DEM | Fc, DEM, siMCT4 | [59] | |
FPBC@SN | Fe2+, Fe3+, SRF, NLG919 | [60] | |
Inhibiting the activity of System Xc- | Ce6-Erastin | Erastin | [66] |
SSZ-Fe2+@DSSD | Fe2+, SSZ | [67] | |
MIL-101(Fe)@SRF | Fe2+, Fe3+, SRF | [68] | |
Delivering exogenous lipid peroxides | IO-LAHP | IO NPs, LAHP | [71] |
RSL3@mPEG-PLys-AA | RSL3, AA | [72] | |
Lecithin@FAC | Fe2+, Fe3+, Lecithin | [73] |